Enovis Valuation Multiples

Enovis Overview

About Enovis

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Founded

1998

HQ

Employees

7.4K

Website

enovis.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $2B

EBITDA: $409M

EV

$3B

Valuation Multiples

Multiples.vc

Start free trial

Enovis Financials

Enovis reported last 12-month revenue of $2B and EBITDA of $409M.

In the same LTM period, Enovis generated $1B in gross profit, $409M in EBITDA, and $196M in net income.

Enovis P&L

In the most recent fiscal year, Enovis reported revenue of $2B and EBITDA of $403M.

Enovis expects next 12-month revenue of XXX and NTM EBITDA of XXX

Enovis Stock Performance

Enovis has current market cap of $1B, and enterprise value of $3B.

Enovis' stock price is $25.70.

Enovis Valuation Multiples

Enovis trades at 1.3x EV/Revenue multiple, and 7.0x EV/EBITDA.

Enovis Financial Valuation Multiples

As of March 31, 2026, Enovis has market cap of $1B and EV of $3B.

Equity research analysts estimate Enovis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Enovis has a P/E ratio of 7.5x.

Enovis Margins & Growth Rates

Enovis' revenue in the last 12 month grew by 5%.

Enovis' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Enovis' rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Enovis' rule of X is 29% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Enovis Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Enovis M&A Activity

Enovis acquired XXX companies to date.

Last acquisition by Enovis was on XXXXXXXX, XXXXX. Enovis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Enovis Investment Activity

Enovis invested in XXX companies to date.

Enovis made its latest investment on XXXXXXXX, XXXXX. Enovis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).